Daan Panneman and Richard Rodenburg, theme Metabolic disorders, have been awarded a grant from Stichting Stofwisselkracht for their proposal entitled “CRISPR/Cas9 knock-in complementation in fibroblasts of mitochondrial disease patients”. Together with Omar Tutakhel and Jan Smeitink, they will investigate the possibility of using CRISPR/Cas9 knock-in to correct genetic variants in patient fibroblasts.
Mitochondrial disorders belong to the most frequently occurring metabolic disorders (incidence estimated 1:5000 live births). The disease onset can be at any age, involving different organs, and with a wide range of clinical signs and symptoms. Establishing a diagnosis is often challenging because of the large number of mitochondrial disease-causing genes (approximately 400 disease-causing genes described to date) and very limited genotype-phenotype correlations.
In the Radboud Center for Mitochondrial Medicine, Whole Exome Sequencing (WES) is used to identify pathogenic genetic variants in patients suspected of a mitochondrial disorder. Based on genetic, clinical, and biochemical data, a diagnosis is made. However, proving a causal relationship between the patient’s phenotype and genetic variants of unknown significance (VUS) is difficult. The current procedures for follow-up investigations to prove causality are time consuming and do not always give clear answers.With this funding we will attempt to optimize the ability to study the causality between VUSs that have been identified in patients and mitochondrial function by using CRISPR/Cas9. With this gene-editing technique, we will repairing the genetic variant in patient fibroblasts restores mitochondrial function. Based on this we can conclude whether the VUS is pathogenic. We postulate that this technique will increase the number of VUSs that can be resolved, improving the diagnostics of mitochondrial disorders and ultimately of other metabolic diseases.
Related news items
Study into better protection for healthcare workers against coronavirus infection19 March 2020
Radboudumc and UMC Utrecht will investigate whether health care workers are better protected against the coronavirus after a vaccination against tuberculosis (BCG vaccine). This vaccine does not directly protect against the coronavirus, but provides a boost to the immune system.read more
Differences in the placental disposition of TNF inhibitors uncovered19 March 2020
In Clinical Pharmacology and Therapeutics, researchers from the Depts. of Pharmacology and Toxicology, Obstetrics and Gynecology, and Health Evidence, in collaboration with Sanquin Diagnostic Services, investigated the placental handling of the TNF inhibitors infliximab and etanercept.read more
Your research story at Bessensap? extended deadline 10 April 202018 March 2020
On Friday 12 June it is your chance to bring your research to the attention of more than 350 science journalists, press officers and researchers.read more
Register for pilot peer coaching for RIMLS PhD candidates17 March 2020
Obtaining your PhD can be a difficult task. In a peer coaching group (“intervisie groep”) you can discuss your (non-technical) problems or dilemmas in a structured way with peers. You can now register for the RIMLS pilot with PhD peer coaching groups. Extended deadline 15 May 2020.read more
Interleukin-37 plays a rol in the pathogenesis and treatment of gout11 March 2020
RIMLS researchers Leo Joosten, Viola Klück and Rosanne van Deuren, in collaboration with the Dept. of Human Genetics, discovered that rare genetic variants in interleukin-37 link the anti-inflammatory cytokine to the pathogenesis and treatment of gout.read more
Jeroen van den Heuvel in Dutch TV program Het Klokhuis9 March 2020
Recently, Jeroen van den Heuvel, research technician at the Dept. of Pharmacology and Toxicology, was seen in the Dutch TV program 'Het Klokhuis" about the effects of painkillers.read more